HIV/Family planning integration

Resource
June 28, 2019
This analysis offers a wide range of scenarios given the considerable uncertainty over ring uptake, consistency of use, and effectiveness, as well as HIV testing, prevention, and treatment use over the next two decades. This could help inform donors and implementers as they decide where to allocate resources in order to maximize the impact of the dapivirine ring in light of funding and implementation constraints.
News
June 26, 2019
Results of a pivotal clinical trial among 7,829 women ages 16-35 in East and Southern Africa provide important evidence to help inform women’s choices for contraception and HIV prevention. The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study found no substantial difference in HIV risk among women using the three methods of contraception in the study – the copper-releasing intrauterine device (Cu-IUD), a levonorgestrel (LNG) implant (Jadelle) and depot medroxyprogesterone acetate-intramuscular (DMPA-IM), also known as Depo-Provera.
Resource
June 25, 2019
Injectable, intrauterine, and implantable contraceptives have been prioritised for programmatic delivery because of high contraceptive efficacy and safety. Robust evidence on the relative risks, particularly HIV susceptibility, and benefits of these contraceptive methods is important to inform women's decision making, provider counselling, and policy maker and regulatory decisions. Our primary objective was to compare HIV incidence among women using DMPA-IM, a copper IUD, or a levonorgestrel (LNG) implant.
Resource
June 13, 2019
Results from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study were released at a session at the 9th South African AIDS Conference (SA AIDS 2019) in Durban, South Africa, on Thursday, June 13th. The session, which included presentations on the primary analysis, was recorded and can be viewed on YouTube here.
Resource
June 13, 2019
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study is an open-label randomised clinical trial comparing three highly effective, reversible methods of contraception — a progestogen-only injectable called depot-medroxyprogesterone acetate (DMPA), a levonorgestrel implant and the non-hormonal copper intrauterine device — to evaluate whether there is any difference in the risk of acquiring HIV infection among users of these methods.Read this fact sheet for more about the ECHO study.
Event
June 5, 2019

It makes logical sense that integrating SRHR and HIV services should be cost effective and some studies have found clear efficiencies in the use of human resources for health (Integra and the Together4SRHR).

Resource
April 12, 2019
Contraceptive adherence during acute and recent HIV-1 infection is important to maternal and child health given the elevated risk of vertical HIV-1 transmission and additional complications of pregnancy. Injectable contraception (IC) is the most common non-barrier modern contraception method used in sub-Saharan Africa (SSA). Adherence to IC after HIV-1 seroconversion is not well understood.
Resource
April 12, 2019
Increased coverage of voluntary medical male circumcision (VMMC) is needed in countries with high HIV prevalence. We applied an HIV-prevention cascade to identify gaps in male circumcision coverage in Zambia.
Resource
April 12, 2019
Unintended pregnancy and HIV infection present dual risks for young women in sub-Saharan Africa. New multipurpose prevention technologies (MPTs) are in development to simultaneously prevent unintended pregnancy and HIV, but there is a need for end-user research to ensure these products suit women's needs. The Tablet, Rings and Injectables as Options (TRIO) for women study took place in Kisumu, Kenya, and Soshanguve, South Africa, with the goal of eliciting young women's feedback on three potential MPTs.